Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 257

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 257
---
 $250.0 million has been drawn.

On November 29, 2024, the
Company appointed Tam, Chun Wa to the Company’s Board of Directors (the “Board”). Mr. Tam will serve as an independent
director. In addition, Mr. Tam has been named to the Audit Committee of the Board. Following the appointment of Mr. Tam, the Board consists
of five members.

On February 28, 2025, the
Company completed its acquisition of the MicroSort technology from Genetics & IVF Institute, Inc. (“GIVF”). Pursuant
to a Purchase Agreement dated January 21, 2025 between the Company and GIVF (“Purchase Agreement”), the Company purchased
all of the Assets (as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to the MicroSort
technology from GIVF for a cash consideration of $750,000 and a share consideration of 125,000 Ordinary Shares (“MicroSort Acquisition”).
Under the terms of the agreement, the Company acquired the technology for US$5 million, which was satisfied through a combination of
US$750,000 in cash and the issuance of 2,500,000 ordinary shares (as was adjusted to 125,000 ordinary shares after the Reverse Stock
Split on February 11, 2025) at a deemed value of US$1.70 per share.

On February 18, 2025, the
Company entered into a cooperation agreement with FERTILITY GROUP LLC (“BOBCARE”) to jointly develop fertility services in
the Kyrgyzstan market. The collaboration aims to combine NewGen’s technical expertise in fertility treatments with BOBCARE’s
market resources in the region. This strategic partnership is anticipated to contribute to NewGen’s market presence over the next
three years, improving the competitive position of both parties in the Kyrgyzstan market. Both companies will work together on several
initiatives, including enhancing clinical protocols and patient management systems, knowledge exchange between fertility specialists,
coordinated marketing and brand-building activities in Kyrgyzstan, and developing specialized fertility treatment options for the regional
market.

<div align='center'>F-41</div>

On March 31, 2025, the Company
terminated the binding term sheet with healthcare company European Wellness Investment Holdings Limited (“EWIHL”) regarding
their previously announced reverse merger transaction. On the grounds of non fulfilment of certain criteria as contained in the term
sheet.

On March